NEW YORK (GenomeWeb News) – Iris International late on Monday announced a deal between its Sample Processing division and Fisher Healthcare to co-market Iris' ThermoBrite Elite instrument for automated fluorescence in situ hybridization sample preparation.
Fisher, a part of Thermo Fisher Scientific, is the first commercial distribution partner for the instrument, Iris said.
Bill Standwill, VP of global sales and marketing for the Iris Sample Processing division, said in a statement that the ThermoBrite Elite instrument is a "natural line extension to the installed base of approximately 5,000 ThermoBrite instruments and will significantly enhance our competitive position in the high growth cytogenetic instrumentation market."
Robert Mello, president of the division, added that expanding its relationship with Fisher "provides a significant domestic sales channel for the ThermoBrite Elite and our future molecular products in this fast growing market."
Iris said that the target market for the instrument is the approximately 4,000 laboratories globally in the clinical and research market that offer FISH testing.
Financial and other terms of the deal were not disclosed.